This finding supported our hypothesis that weak binding between sBCMA-Fc and BAFF is likely to be a contributing factor toward poor therapeutic efficacy in BAFF-driven DLBCL models. The gene discussed is TNFSF13B; the disease is diffuse large B-cell lymphoma.